COMMUNIQUÉS West-GlobeNewswire

TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026
12/11/2025
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders. Presented in [...]
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
12/11/2025
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
12/11/2025
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-label REVEAL-1 Cohort [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
12/11/2025
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest [...]
Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025
12/11/2025
Investigator-initiated study shows potential for EchoSolv AS to drive improved patient outcomes when used to support cardiologist in identifying severe AS particularly in women NEDA study of 1.2M patients’ [...]
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
12/11/2025
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients — KRRO-110 did not reach projected levels of functional protein following a [...]
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
12/11/2025
NurExone Honored at Berlin and Stockholm Conferences for Breakthrough Contributions to Global Life Sciences and Health Innovation TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV [...]
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission – WATERTOWN, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- [...]
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
12/11/2025
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET [...]
Ascendis Pharma Reports Third Quarter 2025 Financial Results
12/11/2025
– Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ® – Q3 2025 operating profit of €11.0 million – TransCon ® CNP (navepegritide) under FDA Priority Review for the treatment of children [...]
Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results
12/11/2025
● Q3 Revenue of $8.8 million ● Q3 Cash Collections of $10.0 million ● Q3 Thyroid test volume up 12% year-over-year to record levels ● Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, [...]
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
12/11/2025
Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform Realigned pipeline [...]
Natural Alternatives International, Inc. Announces 2026 Q1 Results
12/11/2025
CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
12/11/2025
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
12/11/2025
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the [...]
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
12/11/2025
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the [...]
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
12/11/2025
DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Solana Company to Release Third Quarter Operating Results on November 18, 2025
12/11/2025
NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]
Inventiva announces launch of public offering
12/11/2025
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]

Pages